Citations

Clear

246 citation(s) found for "Study, Alfa".

IC‐P‐025: Shanghai community brain health initiative pilot study: Neuropsychological results
Ding, Ding , Guo, Qihao , Mortimer, James A., Copenhaver, Cathleen, Salmon, David P. , Galasko, Douglas, DeCarli, Charles , Petersen, Ron, Borenstein, Amy R., Zhao, Qianhua , Ding, Ding , Dai, Qi , Wu, Yougui , Hong, Zhen

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_1 | Pages: No page available

10.1016/j.jalz.2009.05.045 Get It

P1‐106: Brain changes in 676 ADNI subjects: summary of 10 studies using tensor based‐morphometry and automated hippocampal mapping
Thompson, Paul , Hua, Xue, Morra, Jonathan H., Apostolova, Liana G. , Lee, Suh , Avedissian, Christina, Madsen, Sarah K., Green, Amity E., Toga, Arthur W. , Shaw, Leslie M. , Trojanowski, John Q. , Weiner, Michael W. , Leow, Alex , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_7 | Pages: No page available

10.1016/j.jalz.2009.04.111 Get It

P1‐105: Tensor‐based morphometry as surrogate marker for Alzheimer's disease and mild cognitive impairment: optimizing statistical power
Thompson, Paul , Thompson, Paul, Hua, Xue, Lee, Suh , Ho, April J., Parikshak, Neelrup, Toga, Arthur W. , Weiner, Michael W. , Thompson, Paul M., Thompson, Paul M., Thompson, Paul, Yanovsky, Igor , Leow, Alex , Jack, Clifford R. , Thompson, Paul M., Thompson, Paul M.

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_7 | Pages: No page available

10.1016/j.jalz.2009.04.110 Get It

P2‐024: Examination of default mode network activity along the cognitive continuum: Normal aging, MCI and AD
Avula, Ramesh, Senjem, Matthew L. , Przybelski, Scott A. , Gunter, Jeff, Edmonson, Heidi A. , Petersen, Ronald C. , Machulda, Mary M. , Vemuri, Prashanthi , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R. , Senjem, Matthew L

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_9 | Pages: No page available

10.1016/j.jalz.2009.04.333 Get It

Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease
Roher, Alex E., Esh, Chera L., Kokjohn, Tyler A., Castaño, Eduardo M., Vickle, Gregory D. Van, Kalback, Walter M., Patton, Rebekah , Luehrs, Dean C., Daugs, Ian D., Kuo, Yu‐Min , Emmerling, Mark R., Soares, Holly , Quinn, Joseph F. , Kaye, Jeffrey , Connor, Donald J., Silverberg, Nina, Seward, James D., Beach, Thomas G. , Adler, Charles H. , Sabbagh, Marwan Noel , Quinn, Joseph F

Mayo Clinic

Alzheimer's & Dementia | December 31, 2008 | Volume: 5 | Issue: 1 | Pages: 18-29

10.1016/j.jalz.2008.10.004 | PMID 19118806 Get It

BackgroundWe evaluated the amounts of amyloid beta (Aβ)) peptides in the central nervous system (CNS) and in reservoirs outside the CNS and their potential impact on Aβ plasma levels and Alzheimer's disease (AD) pathology.MethodsAmyloid β levels were measured in (1) the plasma of AD and nondemented (ND) controls in a longitudinal study, (2) the plasma of a cohort of AD patients receiving a cholinesterase inhibitor, and (3) the skeletal muscle, liver, aorta, platelets, leptomeningeal arteries, and in gray and white matter of AD and ND control subjects.ResultsPlasma Aβ levels fluctuated over time and among individuals, suggesting continuous contributions from brain and peripheral tissues and associations with reactive circulating proteins. Arteries with atherosclerosis had larger amounts of Aβ40 than disease‐free vessels. Inactivated platelets contained more Aβ peptides than activated ones. Substantially more Aβ was present in liver samples from ND patients. Overall, AD brain and skeletal muscle contained increased levels of Aβ.ConclusionsEfforts to use plasma levels of Aβ peptides as AD biomarkers or disease‐staging scales have failed. Peripheral tissues might contribute to both the circulating amyloid pool and AD pathology within the brain and its vasculature. The wide spread of plasma Aβ values is also due in part to the ability of Aβ to bind to a variety of plasma and membrane proteins. Sources outside the CNS must be accounted for because pharmacologic interventions to reduce cerebral amyloid are assessed by monitoring Aβ plasma levels. Furthermore, the long‐range impact of Aβ immunotherapy on peripheral Aβ sources should also be considered.
IC‐P3‐165: 3D comparison of low, intermediate and advanced hippocampal atrophy in MCI
Apostolova, Liana G. , Green, Amity H., Hwang, Kristy , Petersen, Ron, Thal, Leon J., Aisen, Paul, DeCarli, Charlie S., Thompson, Paul M. , Jack, Clifford R. , Harvey, Danielle , Cummings, Jeffrey L.

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_2 | Pages: No page available

10.1016/j.jalz.2008.05.109 Get It

P3‐287: TDP‐43 A315T mutation in familial motor neuron disease
Baloh, Robert H. , Chakraverty, Sumi, Mayo, Kevin, Norton, Joanne, Levitch, Denise, Hatanpaa, Kimmo J. , White, Charles H., Bigio, Eileen H. , Caselli, Richard J. , Baker, Matt , Al‐Lozi, Muhammad, Pestronk, Alan , Rademakers, Rosa , Cairns, Nigel J. , Gitcho, Michael A. , Morris, John C. , Goate, Alison

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_18 | Pages: No page available

10.1016/j.jalz.2008.05.1855 Get It

P2‐012: Alzheimer's disease neuroimaging initiative phantom and scanner longitudinal performance
Gunter, Jeff, Borowski, Bret, Britson, Paula J., Ward, Chadwick P., Felmlee, Joel P. , Schuff, Norbert, Weiner, Michael W. , Bernstein, Matt A. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_11 | Pages: No page available

10.1016/j.jalz.2008.05.1092 Get It